These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23235917)

  • 1. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
    Lomax AJ; Hill PA; Ashley DM
    J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma.
    Barakat RK; Singh N; Lal R; Verani RR; Finkel KW; Foringer JR
    Ann Pharmacother; 2007 Apr; 41(4):707-10. PubMed ID: 17374619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
    Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
    Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma - a prospective analysis.
    Wagner CC; Held U; Kofmehl R; Battegay E; Zimmerli L; Hofer S
    Acta Oncol; 2014 Apr; 53(4):572-5. PubMed ID: 24219539
    [No Abstract]   [Full Text] [Related]  

  • 10. Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue?
    Wachter D; Kallenberg K; Wrede A; Schulz-Schaeffer W; Behm T; Rohde V
    J Neurol Surg A Cent Eur Neurosurg; 2012 Nov; 73(6):401-6. PubMed ID: 22777926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma.
    Lomax AJ; Yannakou CK; Rosenthal MA
    Target Oncol; 2013 Jun; 8(2):153-5. PubMed ID: 23430346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in glioblastoma multiforme.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W; Weller M; van den Bent M; Stupp R
    J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract]   [Full Text] [Related]  

  • 16. Bevacizumab as first-line therapy for glioblastoma.
    Piccioni D; Lai A; Nghiemphu P; Cloughesy T
    Future Oncol; 2012 Aug; 8(8):929-38. PubMed ID: 22894667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab and Bevacizumab in Glioblastoma.
    Carter T; Shaw H; Cohn-Brown D; Chester K; Mulholland P
    Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):622-626. PubMed ID: 27169593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and severe acne in a patient treated with bevacizumab.
    Molina-Ruiz AM; Domine M; Requena L
    Int J Dermatol; 2013 Apr; 52(4):486-90. PubMed ID: 23432695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
    Lukas RV; Goldenberg F; Nicholas MK
    J Clin Neurosci; 2012 Sep; 19(9):1310-1. PubMed ID: 22721885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.